W. Whalen

Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

Mario Roederer, Sumana Chakravarty, Martha C Nason, 2016, Nature Medicine.

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

J. Mascola, T. Pierson, C. Andrews, 2017, The Lancet.

Correction: Corrigendum: Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

Andrea A. Berry, S. Hoffman, S. Kappe, 2016, Nature Medicine.

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

J. Mascola, R. Koup, C. Andrews, 2019, The Lancet.

Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

J. Mascola, D. Baltimore, E. Boritz, 2022, Nature Medicine.

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

J. Mascola, R. Koup, J. Casazza, 2022, Nature Medicine.

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults

Carmen M. Graves, J. Mascola, R. Koup, 2023, Science Translational Medicine.